Intervening in disease through genetically-modified bacteria

Area of Science:

• Microbiology
• Biotechnology
• Drug Delivery Systems

Background:

• Advancing technology enables disease molecular basis comprehension, identifying therapeutic proteins like cytokines.
• Clinical use of therapeutic proteins is limited by delivery and synthesis challenges, including degradation and purification costs.
• Genetically modified bacteria present a novel approach to overcome these limitations for targeted protein delivery.

Purpose of the Study:

• To review the methodology of using genetically modified bacteria as drug delivery vehicles.
• To explore the potential of engineered bacteria for therapeutic applications, particularly at mucosal surfaces.
• To discuss the economic and practical advantages of bacterial drug delivery systems.

Main Methods:

• Review of existing literature on genetically modified bacteria for therapeutic protein delivery.
• Analysis of challenges associated with conventional protein-based therapies.
• Exploration of the role of the gut microbiome in health and disease.

Main Results:

• Genetically modified bacteria can effectively deliver therapeutic proteins to targeted sites, especially mucosal surfaces.
• This approach bypasses issues of protein degradation and expensive purification processes.
• Bacterial propagation is cost-effective, making it suitable for developing countries.

Conclusions:

• Genetically modified bacteria represent a promising platform for novel prophylactic and therapeutic interventions.
• Engineering the human microbiome offers significant potential across biology, nanotechnology, and chemistry.
• This methodology inspires new drug delivery systems with broad applicability.